CADTH Canadian Drug Expert Committee recommendation: Cladribine (Mavenclad -- EMD Serono) indication: relapsing-remitting multiple sclerosis
The CADTH Canadian Drug Expert Committee recommends that cladribine be reimbursed as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee recommends that cladribine be reimbursed as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability |
---|---|
Physical Description: | 1 PDF file (8 pages) |